Alnylam Pharmaceuticals Inc (ALNY) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Total Cash From Operating Activities Chart for Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc (ALNY) operating cash flow for FY2025 was USD 524.1M. Alnylam Pharmaceuticals Inc's operating cash flow moved from USD -1.3M in 2002 to USD 524.1M in 2025 over 23 years.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$31.65B
Implied Share Price
$236.56
Enterprise Value
$29.94B
Revenue (TTM)
$4.80B
EBITDA
$1.05B
Profit Margin
16.13%
Trailing P/E
41.65
Forward P/E
27.55
Price/Book (MRQ)
23.62
Price/Sales (TTM)
6.59
EV/EBITDA
27.09
EV/Revenue
6.23
Dividend Yield
—
Book Value
$10.12
Free Cash Flow (FY2025)
$465.38M
Free Cash Flow Yield
1.47%

Snapshot as of 28th August 2026 — not point-in-time controlled, may lag the live market by a few days.